litlas
Log inCreate account

Andrew Blauvelt

Active 1995–2025

213
Papers
32,518
Citations
92
h-index
188
i10-index

Citations

Citations per year for Andrew Blauvelt1986: 1 citations1995: 3 citations1996: 13 citations1997: 14 citations1998: 46 citations1999: 56 citations2000: 38 citations2001: 70 citations2002: 67 citations2003: 83 citations2004: 80 citations2005: 97 citations2006: 84 citations2007: 70 citations2008: 56 citations2009: 67 citations2010: 92 citations2011: 125 citations2012: 106 citations2013: 90 citations2014: 121 citations2015: 84 citations2016: 149 citations2017: 298 citations2018: 383 citations2019: 1,218 citations2020: 1,539 citations2021: 1,666 citations2022: 1,464 citations2023: 1,527 citations2024: 2,137 citations2025: 1,221 citations2026: 11 citations1987–1994: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,837 citing papers, 23.3% of this breakdownGermany: 902 citing papers, 7.4% of this breakdownUnited Kingdom: 818 citing papers, 6.7% of this breakdownChina: 739 citing papers, 6.1% of this breakdownItaly: 736 citing papers, 6% of this breakdownCanada: 642 citing papers, 5.3% of this breakdownJapan: 572 citing papers, 4.7% of this breakdownFrance: 552 citing papers, 4.5% of this breakdownSpain: 385 citing papers, 3.2% of this breakdownSwitzerland: 365 citing papers, 3% of this breakdownNetherlands: 354 citing papers, 2.9% of this breakdownDenmark: 274 citing papers, 2.3% of this breakdown
0%23.3%Other 24.6%

Institutions

Fields

  • Medicine51.5%
  • Immunology and Microbiology40.8%
  • Biochemistry, Genetics and Molecular Biology4.9%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Neuroscience0.6%
  • Agricultural and Biological Sciences0.2%
  • Other1.3%

Topics

  • Psoriasis: Treatment and Pathogenesis14.6%
  • Dermatology and Skin Diseases13.8%
  • Spondyloarthritis Studies and Treatments5.1%
  • Asthma and respiratory diseases4.8%
  • Allergic Rhinitis and Sensitization4.5%
  • T-cell and B-cell Immunology2.1%
  • Other55.1%

Coauthors

All papers

Open in search
  1. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

    Authors: Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky, Lisa A. Beck, Andrew Blauvelt, Michael J. Cork, Jonathan I. Silverberg, Mette Deleuran, Yoko Kataoka, J.‐P. Lacour, Külli Kingo, Margitta Worm, Yves Poulin, Andreas Wollenberg, Yuhwen Soo, Neil M.H. Graham, Gianluca Pirozzi, Bolanle Akinlade, Heribert Staudinger, Vera Mastey, Laurent Eckert, Abhijit Gadkari, Neil Stahl, George D. Yancopoulos, Marius Ardeleanu - New England Journal of Medicine 2016 cited by 2,045

  2. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Authors: Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel - The Lancet 2017 cited by 1,243

  3. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

    Authors: Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky, Margitta Worm, Charles Lynde, J.‐P. Lacour, Lynda Spelman, Norito Katoh, Hidehisa Saeki, Yves Poulin, Aleksandra Lesiak, Leon Kircik, S.H. Cho, Pedro Herranz, Michael J. Cork, Ketty Peris, Louise Abildgaard Steffensen, B K Bang, Alexandra Kuznetsova, T.N. Jensen, Marie Louise Østerdal, Eric L. Simpson, the ECZTRA 1 and ECZTRA 2 study investigators - British Journal of Dermatology 2020 cited by 595

  4. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

    Authors: Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson, Kim Papp, Aileen L. Pangan, Andrew Blauvelt, Diamant Thaçi, Chia‐Yu Chu, Hyuck-Ki Hong, Norito Katoh, Amy S. Paller, Brian Calimlim, Yihua Gu, Xiaofei Hu, Meng Liu, Yang Yang, John Liu, Allan R. Tenorio, Alvina D. Chu, Alan D. Irvine - The Lancet 2021 cited by 543

  5. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

    Authors: Jonathan I. Silverberg, Emma Guttman‐Yassky, Diamant Thaçi, Alan D. Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L. Simpson, Chia‐Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar Pillai, Julien Sénéschal - New England Journal of Medicine 2023 cited by 314

  6. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

    Authors: April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, Elizabeth Colston, John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt - Journal of the American Academy of Dermatology 2022 cited by 347

  7. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis

    Authors: Andrew Blauvelt, Andrea Chiricozzi - Clinical Reviews in Allergy & Immunology 2018 cited by 751

  8. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

    Authors: Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried, Mark Boguniewicz, Lawrence Sher, Melinda Gooderham, Lisa A. Beck, Emma Guttman‐Yassky, David M. Pariser, Andrew Blauvelt, Jamie Weisman, Benjamin Lockshin, Thomas Hultsch, Qin Zhang, Mohamed Kamal, John D. Davis, Bolanle Akinlade, Heribert Staudinger, Jennifer D. Hamilton, Neil M.H. Graham, Gianluca Pirozzi, Abhijit Gadkari, Laurent Eckert, Neil Stahl, George D. Yancopoulos, Marcella Ruddy, Ashish Bansal - JAMA Dermatology 2019 cited by 509

  9. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

    Authors: Andrew Blauvelt, Henrique D. Teixeira, Eric L. Simpson, Antonio Costanzo, Marjolein de Bruin‐Weller, S. Barbarot, Vimal H. Prajapati, Peter Lio, Xiaofei Hu, Tianshuang Wu, John Liu, Barry Ladizinski, Alvina D. Chu, Kilian Eyerich - JAMA Dermatology 2021 cited by 485

  10. Bimekizumab versus Secukinumab in Plaque Psoriasis

    Authors: Kristian Reich, Richard B. Warren, Mark Lebwohl, Melinda Gooderham, Bruce Strober, Richard G. Langley, C. Paul, Dirk De Cuyper, Veerle Vanvoorden, Cynthia Madden, Christopher L. Cioffi, Luke Peterson, Andrew Blauvelt - New England Journal of Medicine 2021 cited by 400

  11. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    Authors: Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball - Journal of the American Academy of Dermatology 2017 cited by 860

  12. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Authors: Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi - New England Journal of Medicine 2016 cited by 838

  13. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    Authors: Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez - The Lancet 2018 cited by 662

  14. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

    Authors: Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P. Rice, Hwanhee Hong, Norito Katoh, Fernando Valenzuela, Marco DiBonaventura, Tamara A. Bratt, Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernán Valdez, Urs Kerkmann - The Lancet 2022 cited by 237

  15. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    Authors: Kristian Reich, Kim Papp, Andrew Blauvelt, Stephen K. Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, N. Cichanowitz, Qing Li, Kenneth Liu, Carmen La Rosa, Stuart Green, Alexa B. Kimball - The Lancet 2017 cited by 556

  16. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

    Authors: Kristian Reich, April W. Armstrong, Richard G. Langley, Susan Flavin, B. Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt - The Lancet 2019 cited by 376

  17. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

    Authors: Kristian Reich, Kim Papp, Andrew Blauvelt, Richard G. Langley, April W. Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, Veerle Vanvoorden, Mark Lebwohl - The Lancet 2021 cited by 297

  18. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

    Authors: Kenneth B. Gordon, Peter Foley, James G. Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher L. Cioffi, Andrew Blauvelt - The Lancet 2021 cited by 284

  19. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

    Authors: Andrew Blauvelt, Jacob P. Thyssen, Emma Guttman‐Yassky, Thomas Bieber, E. Serra‐Baldrich, Eric L. Simpson, David Rosmarin, Hany Elmaraghy, Eric Meskimen, Chitra R Natalie, Zhuqing Liu, Chenjia Xu, Evangeline Pierce, MaryAnn Morgan-Cox, Esther García Gil, Jonathan I. Silverberg - British Journal of Dermatology 2023 cited by 149

  20. Conjunctivitis in dupilumab clinical trials

    Authors: Bolanle Akinlade, Emma Guttman‐Yassky, Marjolein de Bruin‐Weller, Eric L. Simpson, Andrew Blauvelt, Michael J. Cork, Errol P. Prens, Penny A. Asbell, Esen K. Akpek, Jonathan Corren, Claus Bachert, Ikuo Hirano, Jonathan Weyne, Andrew Korotzer, Z. Chen, Thomas Hultsch, Xiaoping Zhu, John D. Davis, Leda Mannent, Jennifer D. Hamilton, Ariel Teper, Heribert Staudinger, E. Rizova, Gianluca Pirozzi, Neil M.H. Graham, Brad Shumel, Marius Ardeleanu, Andreas Wollenberg - British Journal of Dermatology 2019 cited by 422

  21. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis

    Authors: Amy S. Paller, Carsten Flohr, Michael J. Cork, Anthony Bewley, Andrew Blauvelt, Hwanhee Hong, Shinichi Imafuku, Marie L. A. Schuttelaar, Eric L. Simpson, Weily Soong, Petra Arlert, Katja Wendicke Lophaven, Azra Kurbasic, Lise Soldbro, Natacha Strange Vest, Andreas Wollenberg - JAMA Dermatology 2023 cited by 137

  22. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

    Authors: Mette Deleuran, Diamant Thaçi, Lisa A. Beck, Marjolein de Bruin‐Weller, Andrew Blauvelt, Seth Forman, Robert Bissonnette, Kristian Reich, Weily Soong, Iftikhar Hussaın, Peter Foley, Michihiro Hide, Jean‐David Bouaziz, Joel M. Gelfand, Lawrence Sher, Marie L. A. Schuttelaar, Chen Wang, Zhen Chen, Bolanle Akinlade, Abhijit Gadkari, Laurent Eckert, John D. Davis, Manoj Rajadhyaksha, Heribert Staudinger, Neil M.H. Graham, Gianluca Pirozzi, Marius Ardeleanu - Journal of the American Academy of Dermatology 2019 cited by 256

  23. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

    Authors: Eric L. Simpson, Melinda Gooderham, Andreas Wollenberg, Stephan Weidinger, April W. Armstrong, Jennifer Soung, Silvia Mariel Ferrucci, Renata Gontijo Lima, Michael M. Witte, Wen Xu, Hany Elmaraghy, Chitra R Natalie, Evangeline Pierce, Andrew Blauvelt, ADhere Investigators, Abel Jarell, Neil S. Sadick, Howard Sofen, Paul W Wallace, Jose M Carpio, David Greenstein, Angela Moore, Jose M Mendez, Scott Guenthner, Wendy McFalda, Vivian Laquer, Seth Forman, Todd Schlesinger, Andrew Blauvelt, Jeffrey Crowley, Ricardo Tan, Francis J Averill, Rosalyn Elizabeth George, Eddie Armas, Benjamin Lockshin, Jennifer Soung, Walter K. Nahm, Alison Ehrlich, Sunil Dhawan, Eric L. Simpson, Steve Sitar, Jerry Bagel, Phoebe Rich, Bruce Torkan, David F Fivenson, Jamie Weisman, Melody Lynn Stone, April W. Armstrong, Mirwais Saifi, Brad Glick, Melinda Gooderham, Isaiah Day, Lorne Albrecht, Marni Wiseman, David Gratton, Chi-ho Hong, Bernadetta Majorek‐Olechowska, Adam Reich, Beata Kręcisz, Irena Walecka-Herniczek, Jolanta Węgłowska, Beata Bergler‐Czop, Boguslawa Cimoszko, Kamila Padlewska, Maria Czubek, Andreas Pinter, Kristian Reich, Thomas Wildfeuer, Roland Aschoff - JAMA Dermatology 2023 cited by 143

  24. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

    Authors: Kim Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G. Krueger, J.‐P. Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen K. Tyring, B Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J. Padula - New England Journal of Medicine 2017 cited by 511